ID
42549
Beschreibung
Study ID: 110921 Clinical Study ID: 110921 Study Title: A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00811733 Clinicaltrials.gov Link: https://clinicaltrials.gov/ct2/show/NCT00811733 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Ofatumumab Trade Name: N/A Study Indication: Waldenstrom Macroglobulinaemia The primary objective of this open-label, multi-center, Phase II study was to evaluate the safety and efficacy of Ofatumumab in subjects diagnosed with Waldenstrom Macroglobulinaemia. For the study, eligible subjects were enrolled to receive up to 3 cycles of treatment with Ofatumumab. The first cycle consisted of a single dose of 300 mg followed by 3 weekly doses of 1000 mg (Treatment Group A) or 4 weekly doses of 2000 mg (Treatment Group B) of Ofatumumab, with response assessment beginning at Week 12. Based on the Week 12-16 response, eligible subjects could receive up to 2 additional cycles of treatment. This form has to be filled whenever/if additional scans have to be done during study.
Link
https://clinicaltrials.gov/ct2/show/NCT00811733
Stichworte
Versionen (1)
- 25.08.21 25.08.21 -
Rechteinhaber
GlaxoSmithKline
Hochgeladen am
25. August 2021
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY-NC 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
GSK Ofatumumab in Waldenstrom Macroglobulinaemia, NCT00811733
Additional Scan
- StudyEvent: ODM
Beschreibung
Other protocol specified and/or additional scan
Alias
- UMLS CUI-1
- C2348563
- UMLS CUI-2
- C0011923
- UMLS CUI-3
- C0205394
- UMLS CUI-4
- C1524062
Beschreibung
Scan Method
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C0871511
Beschreibung
Date of Scan
Datentyp
date
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C0011008
Beschreibung
Anatomic location of image coverage
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C1515974
Beschreibung
Other anatomic location of image coverage
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C1515974
- UMLS CUI [1,3]
- C0205394
Beschreibung
Reminder: Any new lesions identified need to be indicated on the Response form and the details of the new lesions need to be entered onto the New Lesion form.
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C3146298
Beschreibung
Reminder: Any new lesions identified need to be indicated on the Response form and the details of the new lesions need to be entered onto the New Lesion form.
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205394
Beschreibung
If the result of the scan is unequivocal progression, ensure the Response Assessment form is completed.
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C1274040
Beschreibung
If the result of the scan is unequivocal progression, ensure the Response Assessment form is completed.
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0011923
- UMLS CUI [1,2]
- C1274040
- UMLS CUI [1,3]
- C1629507
Ähnliche Modelle
Additional Scan
- StudyEvent: ODM
C2985720 (UMLS CUI [2])
C0011923 (UMLS CUI-2)
C0205394 (UMLS CUI-3)
C1524062 (UMLS CUI-4)
C0011008 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,2])
C1515974 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,3])
C1274040 (UMLS CUI [1,2])
C1629507 (UMLS CUI [1,3])
Keine Kommentare